Ben Arye Barak - 27 Feb 2024 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
General Counsel
Signature
Steven Robbins, as attorney in fact for Ben Arye, Barak
Issuer symbol
NVCR
Transactions as of
27 Feb 2024
Transactions value $
$3,373,719
Form type
4
Filing time
29 Feb 2024, 16:30:37 UTC
Previous filing
06 Jul 2023
Next filing
06 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $1.62K +128 +0.36% $12.69 35.3K 31 Dec 2023 Direct F1, F2
transaction NVCR Ordinary Shares Award $1.33M +81.8K +231.57% $16.30 117K 27 Feb 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVCR Stock Options (Right to buy) Award $2.04M +125K $16.30 125K 27 Feb 2024 Ordinary Shares 125K $16.30 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2023 through December 31, 2023. This transaction is also exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2023.
F3 Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
F4 Options to buy 125,078 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.